<unk>  is a Endocrine-Metabolic agent that is FDA approved for the treatment of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include vomiting, nausea, pyrexia, peripheral edema, anxiety, headache, abdominal pain, constipation, and diarrhea.
Rasburicase
Galsulfase
Vorinostat
Febuxostat
Pegloticase
Ridaforolimus
Baricitinib
Gilteritinib